Answers are grounded in this paper and cite their sources.
Regulators and industry continue to prioritize survival-based end points rather than patient-experience end points in cancer-drug development. Yet as patients live longer with cancer, they must increasingly choose among agents with varying efficacy–toxicity balances.
No takes yet. Share an insight, caveat, or question.
Ethan Basch (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: